Albuterol Extended Release (Albuterol Sulfate Extended Release) - Summary

SUMMARY

Albuterol extended-release tablets contain albuterol sulfate, the racemic form of albuterol and a relatively selective beta₂-adrenergic bronchodilator, in an extended-release formulation.

Albuterol extended-release tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

NEWS HIGHLIGHTS RELATED TO ALBUTEROL EXTENDED RELEASE

Published Studies Related to Albuterol Extended Release

Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. [2008.01.08]

A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. [2006.11]

Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. [2006.08]

Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. [2006.01]

Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. [2004.03.23]

more>>

Clinical Trials Related to Albuterol Extended Release

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma [Completed]

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients [Active, not recruiting]

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD) [Completed]

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-MDI In Pediatric Asthmatics [Active, not recruiting]

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma [Completed]

more>>